Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 14, No 5 (2018) Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin
"... with atrial fibrillation: those  who have high bleeding and high thromboembolic risk and elderly. The focus ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... In XANTUS study the safety and efficacy of factor Xa inhibitor rivaroxaban were evaluated ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... инсульта и системных эмболий является одной из основных задач в лечении ФП. Длительное время для их ..."
 
Vol 8, No 4 (2012) THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY Abstract  similar documents
M. Yu. Gilyarov
"... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..."
 
Vol 14, No 4 (2018) Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice Abstract  similar documents
N. M. Vorobyeva, O. N. kacheva
"... The possibility of rivaroxaban using in elderly patients with non-valvular atrial fibrillation ..."
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..."
 
Vol 15, No 4 (2019) Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..."
 
Vol 16, No 5 (2020) New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants Abstract  PDF (Eng)  similar documents
K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
"... Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban ..."
 
Vol 14, No 5 (2018) Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA Abstract  similar documents
Bayer Company Press Release
"... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
"... . Direct oral anticoagulants, particularly rivaroxaban, are widely used for deep vein thrombosis/pulmonary ..."
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 16, No 2 (2020) The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment Abstract  similar documents
К. V. Lobastov, I. V. Schastlivtsev
"... ) is associated with an increased risk of VTE recurrence and bleeding, so low molecular weight heparin (LMWH ..."
 
Vol 12, No 1 (2016) Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita Abstract  similar documents
S. N. Bel'diev
"... in plasma concentrations of rivaroxaban that is accompanied by increased risk of bleeding. According ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... risk of bleeding in carriers of CES1 gene rs2244613 polymorphism, there was also a tendency to reduce ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
"... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... the development of bleeding during anticoagulant therapy with direct oral anticoagulants (DOAC). Material ..."
 
Vol 16, No 1 (2020) Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients Abstract  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
"... of bleeding. Studies of the combination of rivaroxaban at a dose of 2.5 mg and standard antiplatelet therapy ..."
 
Vol 16, No 6 (2020) An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? Abstract  similar documents
T. V. Pavlova
"... , the comorbidity increases the risk of bleeding. Older age is also the risk factor of thrombotic and hemorrhagic ..."
 
Vol 16, No 1 (2020) The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation Abstract  similar documents
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva
"... -VASс 4.81±0.4 points) and >1 risk factor for bleeding (HAS-BLED 3.01±0.2 points). The duration ..."
 
Vol 11, No 5 (2015) New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation Abstract  similar documents
article Editorial
"... New data of the real clinical practice confirms low incidence of major bleeding when using ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... of major bleedings significantly increases that considerably complicates the choice of adequate ..."
 
Vol 10, No 3 (2014) PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD Abstract  similar documents
L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko
"... attractive, is rivaroxaban. ..."
 
Vol 14, No 6 (2018) Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem Abstract  PDF (Eng)  similar documents
N. M. Vorobyeva, O. N. Tkacheva
"... of thrombosis, bleeding and death, are discussed. The evidence base, which is quite limited ..."
 
Vol 16, No 4 (2020) The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? Abstract  similar documents
S. Yu. Martsevich
"... . The authors analyzed a large database of patients with atrial fibrillation and concluded that rivaroxaban ..."
 
Vol 13, No 2 (2017) RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY Abstract  similar documents
. Editorial
"... сопоставимая с ацетилсалициловой кислотой очень низкая частота больших кровотечений (≤0,5%). *Ривароксабан в ..."
 
Vol 8, No 3 (2012) RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
M. Yu. Gilyarov
"... . The alternative antithrombotic agents, including rivaroxaban presented along with the traditional drugs (acetyl ..."
 
Vol 10, No 2 (2014) RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL Abstract  similar documents
J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson
"... антиагрегантную терапию. Ривароксабан по сравнению с плацебо увеличивал частоту больших кровотечений,  но не ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
"... The opinion is expressed in some  domestic publications that  rivaroxaban has  the  most ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..."
 
Vol 16, No 2 (2020) The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 14, No 6 (2018) Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding Abstract  PDF (Eng)  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, N. V. Lomakin
"... anticoagulants (DOACs) inhibitors, as antidotes for DOAC when stopping life-threatening bleeding. DOAC therapy ..."
 
Vol 12, No 3 (2016) THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT Abstract  PDF (Eng)  similar documents
S. R. Gilyarevskiy
"... the validity of monotherapy tactics with rivaroxaban in patients with VTE. The results of this study ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... and rivaroxaban). Aim. To assess the influence of apixaban use on the budget as an alternative to warfarin ..."
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 16, No 1 (2020) Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice Abstract  similar documents
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
 
Vol 16, No 3 (2020) Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics? Abstract  similar documents
S. G. Kanorskii
"... of rivaroxaban and aspirin in high-risk groups, the rate of adverse events, including cardiovascular death ..."
 
Vol 16, No 2 (2020) Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function Abstract  similar documents
N. V. Drobotya, E. Sh. Guseynova, A. A. Pirozhenko
"... . Rivaroxaban may meet these requirements; its use has significant advantage in high adherence to therapy. ..."
 
Vol 16, No 4 (2020) Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? Abstract  similar documents
O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova
"... and atherosclerosis of the peripheral arteries using a combination of the anticoagulant – rivaroxaban ..."
 
Vol 14, No 6 (2018) The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . Abstract  PDF (Eng)  similar documents
artilce Editorial
 
Vol 6, No 5 (2010) THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY Abstract  similar documents
T. V. Kozlova, I. M. Makeyeva, V. Y. Doroshina, S. I. Bokareva
"... ) for a long time and needed in dental treatment are discussed. Assessment of bleeding and thromboembolism risk ..."
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... of intracranial bleeding. There was significant increasing number of publications addressed to use of DOACs ..."
 
Vol 14, No 4 (2018) Antithrombotic Therapy after Bleeding in Elderly Polimorbid Patient: Our Time Challenge Abstract  similar documents
M. R. Atabegashvili, M. Yu. Gilyarov, E. V. Konstantinova, A. N. Kostina, A. P. Nesterov, T. D. Pakharkova, A. E. Udovichenko
"... associated with bleeding from the upper sections of the gastrointestinal tract, and severe anemia ..."
 
Vol 14, No 4 (2018) Risk Controlling of Gastrointestinal Bleeding in Comorbid Patients with Cardiovascular Diseases Abstract  similar documents
O. Yu. Chizhova, L. N. Belousova, I. G. Bakulin
"... hemorrhagic complications, especially gastrointestinal bleeding, remain unresolved. Currently ..."
 
Vol 13, No 5 (2017) ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT Abstract  similar documents
S. G. Kanorskii
"... . Rivaroxaban can be given in fixed doses without routine coagulation control, and phase III studies and actual ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... , rivaroxaban and dabigatran. Along with clinical efficacy and safety profile one of the main characteristics ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 15, No 3 (2019) Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities Abstract  similar documents
article Editorial
"... of both coagulation and platelet). Experts noted that combination of rivaroxaban 2.5 mg BID ..."
 
Vol 15, No 6 (2019) New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease Abstract  similar documents
N. B. Perepech
"... , which obtained confirmation of the positive effect of combined therapy with rivaroxaban ..."
 
Vol 16, No 2 (2020) Off-Label Medicines Use: Complex Problem of Modern Clinical Practice Abstract  similar documents
S. R. Gilyarevskiy
 
Vol 13, No 5 (2017) RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE Abstract  similar documents
статья Редакционная
 
Vol 16, No 5 (2020) The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis Abstract  similar documents
S. P. Abdullaev, K. B. Mirzaev, P. O. Bochkov, I. N. Sychev, D. A. Sychev
"... influence on the equilibrium concentration and the risk of bleeding during dabigatran taking. Material ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... % of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4 ..."
 
Vol 16, No 5 (2020) Doctors’ Adherence to the Guidelines on the Oral Anticoagulants Usage Abstract  similar documents
N. B. Perepech, I. E. Mikhailova, A. V. Tregubov
"... .4% of therapists consider prescribing rivaroxaban in a dose of 2.5 mg 2 times a day to a patient suffering from ..."
 
Vol 15, No 5 (2019) Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, S. P. Korchagina, T. M. Ostroumova, M. S. Chernyaeva, A. A. Kirichenko
"... strategy for preventing stroke associated with AF. Among the DOAC class, rivaroxaban is worth noticing ..."
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract  similar documents
article editorial
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... on the risks of ischemic events associated with stenting, the risk of ischemic stroke and bleeding. Use of new ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... of patients with bleeding because of apixaban therapy (including antidotes application), perioperative ..."
 
Vol 15, No 1 (2019) Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City Abstract  similar documents
A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich
"... of bleeding on the HAS-BLED scale. The incidence of ATT at the prehospital stage was assessed depending ..."
 
Vol 14, No 2 (2018) New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion Abstract  similar documents
A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko
"... , that was demonstrated in a recently published study COMPASS. Treatment with rivaroxaban small doses in addition ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 7, No 6 (2011) CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM Abstract  similar documents
Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov
"... является фактором риска эмболии периферических артерий. Вероятность образования внутрижелудочкового тромба ..."
 
Vol 13, No 2 (2017) APPROACHES TO ANTITHROMBOTIC THERAPY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. A. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... . On the other hand, elderlies are at an increased risk of bleeding. In addition, they have important ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..."
 
Vol 15, No 3 (2019) Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation Abstract  similar documents
L. N. Uddin, A. V. Egorov, A. A. Sokolova, N. S. Morozova, D. A. Napalkov, V. V. Fomin
"... of bleeding was maximum during operations for cancer 18.6%, this value was significantly higher compared ..."
 
Vol 15, No 6 (2019) Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) Abstract  similar documents
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..."
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 9, No 6 (2013) THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY Abstract  similar documents
A. V. Shulkin, E. N. Yakusheva, N. M. Popova
"... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..."
 
Vol 12, No 1 (2016) Acute coronary syndrome and renal dysfunction Abstract  similar documents
F. I. Belyalov
"... the risk of bleeding. It is important to aim for treatment based on the evidence-based studies ..."
 
Vol 10, No 4 (2014) OPTIMAL PREVENTION OF HOSPITAL VENOUS THROMBOEMBOLISM WITH THE HELP OF MEDICAL INFORMATION SYSTEM Abstract  similar documents
G. I. Nazarenko, S. A. Payushk, V. A. Otdelenov, E. B. Kleymenova, L. P. Yashina, D. A. Sychev
 
Vol 14, No 2 (2018) WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY Abstract  similar documents
R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin
 
Vol 14, No 3 (2018) EMBOLIC MYOCARDIAL INFARCTION. EXPERIENCE IN DIAGNOSIS AND MANAGEMENT Abstract  similar documents
A. S. Shilova, E. M. Gilyarova, D. A. Andreev, D. Yu. Shchekochikhin, N. A. Novikova, M. Yu. Gilyarov
"... отсутствие признаков обструктивного атеросклероза является эмболия коронарных артерий из источника ..."
 
Vol 12, No 4 (2016) New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Abstract  similar documents
Article Editorial
"... внутричерепных кровотечений на фоне терапии препаратом Ксарелто® (ривароксабан) по сравнению с варфарином у ..."
 
Vol 13, No 1 (2017) ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY Abstract  similar documents
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... candidates for anticoagulant therapy for reasons other  than  bleeding risk or those  who refuse to take oral ..."
 
Vol 12, No 2 (2016) THE RESULTS OF USE OF NEW NATIVE THROMBOLYTIC IN CLINICAL PRACTICE Abstract  similar documents
E. S. Mazur, R. M. Rabinovich, V. V. Mazur, N. S. Kuznetsova, E. A. Kudryashova, S. V. Veselov
"... . Bleedings, anaphylaxis and total mortality were considered. Results. The ST-segment resolution up to 70 ..."
 
Vol 7, No 5 (2011) NEW ANTIPLATELET DRUGS. PART 2 Abstract  similar documents
A. B. Sumarokov
"... of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is still very ..."
 
Vol 7, No 1 (2011) NEW ANTIPLATELET DRUGS (PART 1) Abstract  similar documents
A. B. Sumarokov
"... of excessive action leading to the bleeding. Possibility to control pharmacodynamics effects of antiplatelet ..."
 
Vol 9, No 5 (2013) PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
"... cardioversion; in invasive or surgical procedures; during bleeding. Possible organizational system ..."
 
Vol 13, No 4 (2017) COMPARATIVE RESULTS OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE AND TENECTEPLASE USE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN REAL CLINICAL PRACTICE Abstract  similar documents
E. S. Mazur, R. M. Rabinovich, V. V. Mazur, N. S. Kuznetsova, E. A. Kudryashova, S. V. Veselov, V. V. Bobkov, D. Yu. Platonov
"... reperfusion criteria were evaluated as well as clinical outcomes – mortality, reinfarction, stroke, bleeding ..."
 
Vol 7, No 4 (2011) EFFICACY AND SAFETY OF GLYCOPROTEIN IIB/IIIA BLOCKER MONOFRAM IN CORONARY STENTING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION Abstract  similar documents
E. I. Makhiyanova, A. S. Galyavich
"... patients. Deaths, stent thrombosis, individual intolerance, allergic reactions, bleeding were registered ..."
 
Vol 14, No 4 (2018) Elderly Patient Management Problems: Antithrombotic Therapy Selection Features. Clinical Case Abstract  similar documents
D. U. Akasheva, E. S. Bulgakova, I. S. Yavelov, A. Yu. Gorshkov, O. M. Drapkina
"... and bleeding complications associated with antithrombotic drugs using. Antithrombotic drug choice is based ..."
 
Vol 14, No 5 (2018) Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report) Abstract  similar documents
G. S. Krasnov, I. V. Kazancev
"... fibrillation and comorbidity. The patient had excessive polypharmacy level (11 drugs). Minor bleeding developed ..."
 
Vol 14, No 6 (2018) Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice Abstract  PDF (Eng)  similar documents
K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova
"... was prescribed in 11 (64.7%) cases and rivaroxaban – in 6 (35.3%). Conclusion. In real clinical practice ..."
 
Vol 13, No 5 (2017) INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION Abstract  similar documents
E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash
"... of bleeding compared with the clopidogrel group both in the hospital period and during the year after ..."
 
Vol 12, No 4 (2016) The use of oral anticoagulants in patients with atrial fibrillation: cohort study data Abstract  similar documents
O. V. Gaisenok, A. S. Leonov
"... .3%. The reasons for the lack of OAC use were: contraindications (high risk of hemorrhage or bleeding history) – 5 ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..."
 
Vol 12, No 1 (2016) Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis Abstract  similar documents
V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov
"... . Meta-analysis of the safety of the NOACs suggested significant reduction of risk of major bleeding ..."
 
Vol 3, No 2 (2007) VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY Abstract  similar documents
D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes
"... with drugs of this group deals with high risk of bleeding including fatal one. Latest decade studies showed ..."
 
Vol 14, No 6 (2018) P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel Abstract  PDF (Eng)  similar documents
N. M. Vorobyeva
"... with a significant reduction in the risk of ischemic complications and mortality with an acceptable risk of bleeding ..."
 
Vol 15, No 5 (2019) Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry Abstract  similar documents
Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan
"... . To develop a model and software module for predicting possible bleeding in patients with ACS combined with AF ..."
 
Vol 12, No 6 (2016) THE USE OF ENOXAPARIN IN ACUTE CORONARY SYNDROME Abstract  similar documents
E. A. Smirnova, S. S. Yakushin
"... of bleeding. Fondaparinux has optimal efficacy/safety profile in ACS with no ST elevation, regardless ..."
 
Vol 16, No 2 (2020) Risk Factors, Clinical Features of the Course of Myocardial Infarction and Treatment of Young Patients Based on Two Hospital Registries Abstract  similar documents
O. L. Barbarash, D. Yu. Sedykh, I. S. Bykova, V. V. Kashtalap, A. D. Erlich
"... a tendency to bleeding (p=0.001). One year after referent MI a high proportion of repeated non-fatal MI (p=0 ..."
 
Vol 13, No 1 (2017) RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION Abstract  similar documents
V. B. Kostogryz
"... and small bleedings were not observed, as well as allergic reactions. In the group of patients who underwent ..."
 
Vol 9, No 6 (2013) THROMBOLYSIS OR PRIMARY PCI FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION? THE STREAM TRIAL (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION) Abstract  similar documents
V. A. Sulimov
"... of tenecteplase in patients ≥75 years: 0.5% vs. 0.3%, p=0.45). The rate of non- intracranial bleeding in two ..."
 
Vol 14, No 1 (2018) COMORBID PATIENT IN GASTROENTEROLOGY: INDIVIDUAL APPROACH Abstract  similar documents
I. G. Bakulin, S. A. Sayganov, M. I. Skalinskaya, E. V. Skazyayeva, I. V. Lapinskii
"... cardiovascular risk taking acetylsalicylic acid and having a high risk of gastrointestinal tract bleeding ..."
 
1 - 100 of 115 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)